CM
CMB.AU Cambium Bio Ltd
- Market cap
- AUD 11.8M
- P/E
- -
- P/B
- 4.95x
- ROE
- -172.2%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CMB.AU undervalued?
Graham numberThe Graham number of Cambium Bio Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cambium Bio Ltd fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-172.2%), below 10%.
ROA 0/1
Return on assets (-108.8%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (18.4%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.9%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.9x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cambium Bio Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Full company profileCambium Bio Ltd financial statements
Cambium Bio Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.99M | 575K | 25.1K | 1.66M | 7.07M | 0.00 | 0.00 | 719.00 | 670K | 642K |
| Gross Profit | 9.61M | 227K | -271K | 1.66M | 7.96M | -25.0K | -6.42K | 79.8K | 464K | 579K |
| Operating Income | 976K | -7.32M | -6.87M | -3.28M | 1.64M | -4.65M | -2.25M | -1.83M | -4.30M | -4.36M |
| EBITDA | 1.01M | -6.94M | -6.75M | -1.22M | 2.37M | -4.74M | -3.08M | -1.98M | -3.80M | -4.36M |
| Net Income | 3.27M | -5.18M | -6.02M | -894K | 2.76M | -4.31M | -3.38M | -2.26M | -3.84M | -4.10M |
| EPS | 1.53 | -2.43 | -2.82 | -0.34 | 0.01 | -1.41 | -1.10 | -0.54 | -0.21 | -0.17 |
| Balance Sheet | ||||||||||
| Total Assets | 9.16M | 4.98M | 2.54M | 4.79M | 8.51M | 2.55M | 2.46M | 5.65M | 3.30M | 3.76M |
| Total Liabilities | 1.06M | 2.06M | 8.93M | 3.70M | 4.36M | 1.48M | 2.59M | 2.87M | 1.46M | 1.38M |
| Shareholders' Equity | 8.10M | 2.92M | -6.39M | 1.09M | 4.15M | 1.07M | -1.81M | 2.78M | 1.84M | 2.38M |
| Cash & Short-term Investments | 4.14M | 1.09M | 255K | 982K | 3.79M | 164K | 303K | 2.86M | 166K | 1.12M |
| Total Debt | - | 1.00M | 3.78M | 1.12M | 13.8K | 1.01M | 1.95M | 468K | 483K | 165K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.59M | -4.25M | -3.61M | -1.94M | 2.42M | -3.59M | -660K | -156K | -5.24M | -2.81M |
| Capital Expenditure | 150K | 151K | 7.62K | 7.78K | 7.78K | 8.47K | 4.00 | 4.00 | 5.26K | 2.64K |
| Free Cash Flow | 3.44M | -4.40M | -3.62M | -1.94M | 2.41M | -3.60M | -660K | -156K | -5.25M | -2.81M |
| Ratios | ||||||||||
| ROE | 40.4% | -177.4% | - | -81.7% | 66.6% | -401.0% | - | -81.2% | -209.4% | -172.2% |
| ROA | 35.7% | -104.0% | -237.0% | -18.7% | 32.4% | -168.7% | -137.0% | -39.9% | -116.7% | -108.8% |
| Net Profit Margin | 32.7% | -901.0% | -24,024.4% | -53.7% | 39.0% | - | - | -313,736.4% | -573.7% | -638.4% |
| Debt to Equity | - | 0.34x | - | 1.02x | 0.00x | 0.94x | - | 0.17x | 0.26x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cambium Bio Ltd dividends
Cambium Bio Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:100 on Jul 4, 2024.
Who owns Cambium Bio Ltd
- Insiders 89.57%
- Institutions 0.00%
- Public & others 10.43%
- Shares outstanding 29.4M
- Free float 3.74M
Cambium Bio Ltd company profile
- Company name
- Cambium Bio Ltd
- Ticker
- CMB.AU
- ISIN
- AU000000RGS6
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Unit 2.06/31 Lexington Dr, Bella Vista, NSW, Australia, 2153
- Phone
- 61 13 0099 5098
- Website
- cambium.bio
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Cambium Bio Ltd management
3- Dr. Edmund Kemp Waller FACP, M.D., Ph.D.Chairman & Chief Scientific Officer
- Mr. Karolis Rosickas M.B.A., M.S.Chief Executive Officer
- Ms. Olga SmejkalovaCompany Secretary